SciClone Pharmaceuticals Inc
岩松(Phil)常 has a solid work experience in the pharmaceutical industry. 岩松(Phil) started their career in 2003 as a National Commercial Manager at Bristol-Myers Squibb and worked there until 2008. 岩松(Phil) then joined Medtronic as a National Sales Manager and later became a Senior Marketing Manager. In 2013, they joined SciClone Pharmaceuticals, where they held various roles including General Manager in the Premier Care division, VP in Market Access and Commercial Operation, and General Manager in the Oncology division. As of 2017, they were serving as the Vice President and General Manager of ONCO at SciClone Pharmaceuticals.
岩松(Phil)常 completed their Bachelor of Applied Science (B.A.Sc.) degree in Biochemistry from Jilin University, an institution they attended from 1986 to 1991. 岩松(Phil) then pursued further education and obtained a Master of Business Administration (M.B.A.) degree with a focus on EMBA from Shanghai Jiao Tong University, where they studied from 2006 to 2009.
This person is not in any offices
SciClone Pharmaceuticals Inc
SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.